Generic liraglutide cash prices undercut weekly GLP-1 brands by as much as elevenfold
Same-day GoodRx cash prices show generic liraglutide selling for a fraction of what Ozempic and Mounjaro listings show, with the discount varying sharply by carton and pharmacy.
Cash prices for generic liraglutide ran as low as $112.19 for a two-pen carton on Sept. 14, 2026, while GoodRx listings for Ozempic and Mounjaro stayed above $1,200 that day [1][2].
GoodRx listed the generic sold under the Victoza label at $112.19 for a two-pen diabetes carton with a coupon, against an average retail price of $615.85 for the same carton [1]. A three-pen carton of the same product was listed at $154.01 against $924.00 retail [1]. The generic sold under the Saxenda label, a five-pen weight-management carton, was listed at $372.45 against $717.63 retail [2]. The Victoza page states that liraglutide is now available only as a generic drug [1].
On the same pages, GoodRx displayed Ozempic at $1,209.15 and Mounjaro at $1,310.99, with a second Mounjaro listing at $1,391.96 [1][2]. Zepbound appeared at $587.01 [1][2]. Those pages also showed "as low as $25.00" figures for Ozempic, Wegovy, Mounjaro and Zepbound, which reflect coupon or savings programs rather than cash prices [1][2]. Measured against the $1,209.15 Ozempic listing, the $112.19 generic liraglutide price is roughly eleven times lower, while the $372.45 weight-management carton is about three times lower.
Prices for the same carton varied widely by pharmacy. The five-pen Saxenda carton ranged from $372.45 at Walgreens and Walgreens Specialty Pharmacy to $570.06 at CVS, $732.12 at Walmart Neighborhood Market, $1,236 at Walmart and $1,241 at Costco [2]. The two-pen Victoza carton ranged from $101.90 at CVS with the GoodRx Companion program to $206.38 at Walmart, $217.71 at Walgreens and $497.80 at Costco [1]. GoodRx cautions that the retail figures it shows are average costs users pay, not pricing at a specific location, and that coupon prices can change without notice [1].
The Victoza page carries several different reference prices for the same two-pen carton: the dosage table lists $615.85 retail, the page's standard price section lists $305.19 retail, and a separate line says the drug is available "as low as $102.40," described as 77% off an average retail price of $455.02 [1].
The FDA's drug code directory returned 62 entries for liraglutide as of Sept. 11, 2026, a count that includes bulk ingredient records as well as finished cartons [3]. Finished products referencing Victoza include the original from Novo Nordisk under application NDA022341, a generic from Meitheal Pharmaceuticals first marketed April 2, 2025 under ANDA218115, and a generic from Teva Pharmaceuticals first marketed Aug. 28, 2025 under ANDA214568 [3]. Saxenda appears under NDA206321 [3].
Why it matters for patients
Liraglutide is a different molecule from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), and a price gap does not make them interchangeable [1][2][3]. Whether one of these medicines can stand in for another is a decision for a prescriber, and the pricing pages do not address it.
The figures above are cash prices. They do not show what any individual pays through insurance, and the pages do not describe how plans cover the generic liraglutide products. For people paying out of pocket, the practical detail is that the same carton carries very different prices at different chains on the same day — a spread of several hundred dollars for the five-pen carton [2].
The size of the discount also depends on which carton is involved. The diabetes carton showed the widest spread against brand listings, while the weight-management carton was closer to the brand prices. The pages do not explain why that difference exists, and they do not say how widely the generic products are stocked.
What happens next
No company or regulator announcements about future liraglutide pricing appear in these listings. GoodRx says its coupon prices are subject to change without notice and stamps the prices shown as last updated on 09/14/26 [1][2]. The FDA's drug code directory, last updated Sept. 11, 2026, lists one liraglutide carton from Teva with a marketing end date of Sept. 30, 2027 [3]. Whether additional generic versions launch, and where cash prices settle, has not been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.